TearScience, a Morrisville, North Carolina-based medical device company, completed a $44.5m Series C funding.The round includes new investors Essex Woodlands Health Ventures, Investor Growth Capital and General Catalyst, as well as existing investors, De Novo Ventures, Spray Ventures and Quaker Bio Ventures.
The funding will allow the company to commercialize its devices designed for use by eye care professionals to diagnose and treat the most common form of chronic dry eye disease.
TearScience has achieved European certification, CE Mark, to market its devices in Europe and is currently seeking U.S. FDA clearance.
The products will be commercially available within the next 12 months.
FinSMEs
05/05/2010